All Stories

  1. First in vivo evaluation of the radiolabelled Hsp90 inhibitor [11C]Onalespib for cancer and brain PET imaging

    Article • August 2026, Springer Science + Business Media

    Guy Bormans

  2. Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [18F]AlF-NOTA-SC, [177Lu]Lu-BL02, and [161Tb]Tb-BL02 for Theranostic Development

    Article • Pharmaceuticals, July 2026, MDPI AG

    Guy Bormans

  3. Affinity- and Format-Dependent Pharmacokinetics of 89Zr-Labeled Albumin-Binding VHH Constructs

    Article • Pharmaceuticals, January 2026, MDPI AG

    Guy Bormans

  4. RBIO-09. Preclinical evaluation of the synergistic effect of heat shock protein 90 inhibitors with temozolomide and external beam radiotherapy in glioblastoma models

    Article • Neuro-Oncology, November 2025, Oxford University Press (OUP)

    Guy Bormans

  5. [11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics

    Article • EJNMMI Radiopharmacy and Chemistry, September 2025, Springer Science + Business Media

    Guy Bormans

  6. In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy

    Article • Cell Stress and Chaperones, September 2025, Elsevier

    Guy Bormans

  7. Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain

    Article • European Journal of Pediatrics, July 2025, Springer Science + Business Media

    Guy Bormans

  8. Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia

    Article • Clinical Epigenetics, July 2025, Springer Science + Business Media

    Guy Bormans

  9. PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease

    Article • European Journal of Pediatrics, June 2025, Springer Science + Business Media

    Guy Bormans

  10. Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT

    Article • EJNMMI Reports, May 2025, Springer Science + Business Media

    Guy Bormans

  11. In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration

    Article • Journal of Nuclear Medicine, April 2025, Society of Nuclear Medicine

    Guy Bormans

  12. Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging

    Article • Journal of Labelled Compounds and Radiopharmaceuticals, April 2025, Wiley

    Guy Bormans

  13. Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography

    Article • Bioconjugate Chemistry, March 2025, American Chemical Society (ACS)

    Guy Bormans

  14. Development and evaluation of Hsp90-targeting nanobodies for visualisation of extracellular Hsp90 in tumours using PET imaging

    Article • EJNMMI Radiopharmacy and Chemistry, February 2025, Springer Science + Business Media

    Guy Bormans

  15. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein

    Article • Fluids and Barriers of the CNS, January 2025, Springer Science + Business Media

    Guy Bormans

  16. Development and evaluation of deuterated [18F]JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain

    Article • EJNMMI Radiopharmacy and Chemistry, December 2024, Springer Science + Business Media

    Guy Bormans

  17. Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924

    Article • European Journal of Pediatrics, December 2024, Springer Science + Business Media

    Guy Bormans

  18. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein

    Article • November 2024, Cold Spring Harbor Laboratory Press

    Guy Bormans

  19. Development and Evaluation of Deuterated [18F]JHU94620 Isotopologues for the Non-invasive Assessment of the Cannabinoid Type 2 Receptor in Brain

    Article • October 2024, Wiley

    Guy Bormans

  20. HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics

    Article • Haematologica, October 2024, Ferrata Storti Foundation (Haematologica)

    Guy Bormans

  21. Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl...

    Article • ACS Pharmacology & Translational Science, September 2024, American Chemical Society (ACS)

    Guy Bormans

  22. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a mult...

    Article • Journal of Neuroendocrinology, June 2024, Wiley

    Guy Bormans

  23. Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging

    Article • Nuclear Medicine and Biology, May 2024, Elsevier

    Guy Bormans

  24. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    Article • EJNMMI Radiopharmacy and Chemistry, October 2023, Springer Science + Business Media

    Guy Bormans

  25. Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [18F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET

    Article • Journal of Medicinal Chemistry, October 2023, American Chemical Society (ACS)

    Guy Bormans

  26. Preclinical Evaluation of Novel PET Probes for Dementia

    Article • Seminars in Nuclear Medicine, September 2023, Elsevier

    Guy Bormans

  27. Radiopharmaceuticals for Cancer Imaging and Therapy

    Article • Pharmaceutics, August 2023, MDPI AG

    Guy Bormans

  28. Author Correction: Reverse engineering synthetic antiviral amyloids

    Article • Nature Communications, June 2023, Springer Science + Business Media

    Johan Neyts, Guy Bormans

  29. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

    Article • EJNMMI Research, June 2023, Springer Science + Business Media

    Guy Bormans

  30. Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist

    Article • Nuclear Medicine and Biology, March 2023, Elsevier

    Guy Bormans

  31. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging

    Article • EJNMMI Radiopharmacy and Chemistry, January 2023, Springer Science + Business Media

    Guy Bormans

  32. 18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study

    Article • European Journal of Hybrid Imaging, January 2023, Springer Science + Business Media

    Guy Bormans

  33. In Vivo Detection of Neurofibrillary Tangles by 18 F-MK-6240 PET/MR in Patients With Ischemic Stroke

    Article • Neurology, January 2023, Wolters Kluwer Health

    Guy Bormans

  34. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/β-Hydrolase Domain 6 (ABHD6)

    Article • Journal of Medicinal Chemistry, December 2022, American Chemical Society (ACS)

    Guy Bormans

  35. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging

    Article • December 2022, Springer Science + Business Media

    Guy Bormans

  36. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients

    Article • European Journal of Pediatrics, November 2022, Springer Science + Business Media

    Guy Bormans

  37. 18F-AlF-NOTA-Octreotide Outperforms68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study

    Article • Journal of Nuclear Medicine, October 2022, Society of Nuclear Medicine

    Guy Bormans

  38. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin

    Article • European Journal of Pediatrics, August 2022, Springer Science + Business Media

    Guy Bormans

  39. Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET

    Article • Journal of Medicinal Chemistry, June 2022, American Chemical Society (ACS)

    Guy Bormans

  40. Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats

    Article • European Journal of Pediatrics, May 2022, Springer Science + Business Media

    Guy Bormans

  41. The PET tracer [ 11 C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease

    Article • Science Translational Medicine, January 2022, American Association for the Advancement of Science

    Guy Bormans

  42. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals

    Article • Theranostics, January 2022, Ivyspring International Publisher

    dr Willy Gsell, Guy Bormans

  43. Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults

    Article • Alzheimer s & Dementia Translational Research & Clinical Interventions, January 2022, Wiley

    Guy Bormans

  44. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy

    Article • Pharmaceutics, October 2021, MDPI AG

    Guy Bormans

  45. Preclinical Evaluation of [11C]YC-72-AB85 for In Vivo Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography

    Article • ACS Chemical Neuroscience, October 2021, American Chemical Society (ACS)

    Guy Bormans

  46. Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets

    Article • Bioconjugate Chemistry, September 2021, American Chemical Society (ACS)

    Guy Bormans

  47. Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability

    Article • Frontiers in Medicine, August 2021, Frontiers

    Guy Bormans

  48. Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain

    Article • International Journal of Molecular Sciences, July 2021, MDPI AG

    Guy Bormans

  49. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats

    Article • European Journal of Pediatrics, June 2021, Springer Science + Business Media

    Guy Bormans

  50. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density

    Article • EJNMMI Physics, April 2021, Springer Science + Business Media

    Guy Bormans

  51. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    Article • EJNMMI Radiopharmacy and Chemistry, March 2021, Springer Science + Business Media

    Guy Bormans

  52. On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion

    Article • Nuclear Medicine and Biology, February 2021, Elsevier

    Guy Bormans

  53. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model

    Article • Nuclear Medicine and Biology, February 2021, Elsevier

    Guy Bormans

  54. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)

    Article • EJNMMI Radiopharmacy and Chemistry, January 2021, Springer Science + Business Media

    Guy Bormans

  55. Photo isomerization of cis‐cyclooctene to trans‐cyclooctene: Integration of a micro‐flow reactor and separation by specific adsorption

    Article • AIChE Journal, October 2020, Wiley

    Guy Bormans

  56. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain

    Article • European Journal of Pediatrics, July 2020, Springer Science + Business Media

    Guy Bormans

  57. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients

    Article • European Journal of Pediatrics, July 2020, Springer Science + Business Media

    Guy Bormans

  58. Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects

    Article • The Quarterly Journal of Nuclear Medicine and Molecular Imaging, July 2020, Edizioni Minerva Medica

    Guy Bormans

  59. Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution

    Article • EJNMMI Research, June 2020, Springer Science + Business Media

    dr Willy Gsell, Guy Bormans

  60. Reverse engineering synthetic antiviral amyloids

    Article • Nature Communications, June 2020, Springer Science + Business Media

    Johan Neyts, Guy Bormans

  61. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

    Article • Clinical Epigenetics, May 2020, Springer Science + Business Media

    Guy Bormans

  62. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour

    Article • European Journal of Pediatrics, May 2020, Springer Science + Business Media

    Guy Bormans

  63. Photoisomerization of cis- to trans-cyclooctene: integration of a micro-flow reactor & separation by specific adsorption

    Article • May 2020, Wiley

    Guy Bormans

  64. Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging

    Article • Molecules, April 2020, MDPI AG

    Guy Bormans, Prof Christian GA Vanhove

  65. Translation of HDAC6 PET Imaging Using [18F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates

    Article • ACS Chemical Neuroscience, March 2020, American Chemical Society (ACS)

    Guy Bormans

  66. Development and Evaluation of Interleukin-2–Derived Radiotracers for PET Imaging of T Cells in Mice

    Article • Journal of Nuclear Medicine, February 2020, Society of Nuclear Medicine

    Guy Bormans

  67. Correction to Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer

    Article • Journal of Medicinal Chemistry, February 2020, American Chemical Society (ACS)

    Guy Bormans

  68. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper

    Article • Journal of Cerebral Blood Flow & Metabolism, February 2020, SAGE Publications

    Guy Bormans, Sara Marie Ulv Larsen

  69. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation

    Article • Diagnostics, January 2020, MDPI AG

    Guy Bormans

  70. Automated GMP compliant production of [18F]AlF-NOTA-octreotide

    Article • EJNMMI Radiopharmacy and Chemistry, January 2020, Springer Science + Business Media

    Guy Bormans, dr Willy Gsell

  71. Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI

    Article • Translational Oncology, January 2020, Elsevier

    Guy Bormans

  72. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients

    Article • European Journal of Pediatrics, December 2019, Springer Science + Business Media

    Guy Bormans

  73. Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging

    Article • Nanomaterials, November 2019, MDPI AG

    Guy Bormans, dr Willy Gsell

  74. The Changing Landscape of Early Medicines Development: Be Prepared

    Article • October 2019, Frontiers

    Guy Bormans

  75. Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced α-synucleinopathy

    Article • Experimental Neurology, October 2019, Elsevier

    Guy Bormans

  76. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study

    Article • Journal of Nuclear Medicine, September 2019, Society of Nuclear Medicine

    Guy Bormans

  77. Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients

    Article • Journal of Nuclear Medicine, September 2019, Society of Nuclear Medicine

    Guy Bormans

  78. Design and Challenges of Radiopharmaceuticals

    Article • Seminars in Nuclear Medicine, September 2019, Elsevier

    Guy Bormans

  79. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient

    Article • European Journal of Pediatrics, July 2019, Springer Science + Business Media

    Guy Bormans

  80. Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson’s Disease

    Article • Frontiers in Neuroscience, July 2019, Frontiers

    Guy Bormans

  81. Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma

    Article • Nuclear Medicine and Biology, July 2019, Elsevier

    Guy Bormans

  82. In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration

    Article • July 2019, Institute of Electrical & Electronics Engineers (IEEE)

    Guy Bormans

  83. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers

    Article • European Journal of Pediatrics, June 2019, Springer Science + Business Media

    Guy Bormans

  84. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles

    Article • Molecular Imaging and Biology, May 2019, Springer Science + Business Media

    Guy Bormans

  85. Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer

    Article • Journal of Medicinal Chemistry, February 2019, American Chemical Society (ACS)

    Guy Bormans

  86. Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET

    Article • British Journal of Pharmacology, January 2019, Wiley

    Guy Bormans

  87. Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain

    Article • EJNMMI Research, December 2018, Springer Science + Business Media

    Guy Bormans

  88. 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446

    Article • Journal of Nuclear Medicine, September 2018, Society of Nuclear Medicine

    Guy Bormans

  89. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method

    Article • Nature Protocols, September 2018, Springer Science + Business Media

    Guy Bormans

  90. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia

    Article • Alzheimer s Research & Therapy, July 2018, Springer Science + Business Media

    Guy Bormans

  91. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers

    Article • World Journal of Gastroenterology, July 2018, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Guy Bormans

  92. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI‐microangiography‐histopathology in rats

    Article • International Journal of Cancer, July 2018, Wiley

    Guy Bormans

  93. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants

    Article • European Journal of Pediatrics, June 2018, Springer Science + Business Media

    Guy Bormans

  94. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles

    Article • Journal of Nuclear Medicine, June 2018, Society of Nuclear Medicine

    Guy Bormans

  95. Effects of alcohol exposure on the glutamatergic system: a combined longitudinal 18 F-FPEB and 1 H-MRS study in rats

    Article • Addiction Biology, May 2018, Wiley

    Guy Bormans, dr Willy Gsell

  96. Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers

    Article • Clinical and Translational Science, March 2018, Wiley

    Guy Bormans

  97. Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats

    Article • Journal of Nuclear Medicine, March 2018, Society of Nuclear Medicine

    Guy Bormans

  98. Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence

    Article • Journal of Nuclear Medicine, January 2018, Society of Nuclear Medicine

    Guy Bormans

  99. Pretargeted PET Imaging Using a Bioorthogonal 18F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model

    Article • Bioconjugate Chemistry, December 2017, American Chemical Society (ACS)

    Guy Bormans

  100. Position statement on radiopharmaceutical production for clinical trials

    Article • EJNMMI Radiopharmacy and Chemistry, September 2017, Springer Science + Business Media

    Guy Bormans

  101. Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study

    Article • Addiction Biology, September 2017, Wiley

    Guy Bormans

  102. Synthesis and preclinical evaluation of [ 11 C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)

    Article • European Journal of Medicinal Chemistry, August 2017, Elsevier

    Guy Bormans

  103. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P

    Article • Oncotarget, July 2017, Impact Journals, LLC

    Guy Bormans

  104. Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

    Article • Molecular Imaging and Biology, July 2017, Springer Science + Business Media

    Guy Bormans

  105. Synthesis, Enzyme Assays and Molecular Docking Studies of Fluorina ted Bioisosteres of Santacruzamate A as Potential HDAC Tracers

    Article • Letters in Drug Design & Discovery, June 2017, Bentham Science Publishers

    Guy Bormans

  106. Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease

    Article • Movement Disorders, April 2017, Wiley

    Guy Bormans

  107. cGMP production of the radiopharmaceutical [18F]MK-6240 for PET imaging of human neurofibrillary tangles

    Article • Journal of Labelled Compounds and Radiopharmaceuticals, March 2017, Wiley

    Guy Bormans

  108. Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging

    Article • Journal of Nuclear Medicine, February 2017, Society of Nuclear Medicine

    Guy Bormans

  109. Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging

    Article • Theranostics, January 2017, Ivyspring International Publisher

    Guy Bormans

  110. Cholinergic depletion and basal forebrain volume in primary progressive aphasia

    Article • NeuroImage Clinical, January 2017, Elsevier

    Guy Bormans

  111. Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels–Alder reactions. Potential applications for pretargeted in vivo PET imaging

    Article • Chemical Science, January 2017, Royal Society of Chemistry

    Guy Bormans

  112. Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)

    Article • Journal of Medicinal Chemistry, December 2016, American Chemical Society (ACS)

    Guy Bormans

  113. Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO2: Opportunities for 11C Radiochemistry

    Article • ChemCatChem, November 2016, Wiley

    Guy Bormans

  114. The effect of isoflurane on 18F-FDG uptake in the rat brain: a fully conscious dynamic PET study using motion compensation

    Article • EJNMMI Research, November 2016, Springer Science + Business Media

    Guy Bormans

  115. De novo design of a biologically active amyloid

    Article • Science, November 2016, American Association for the Advancement of Science

    Guy Bormans

  116. [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP

    Article • Journal of Neurochemistry, November 2016, Wiley

    Guy Bormans

  117. Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3

    Article • Frontiers in Neuroscience, September 2016, Frontiers

    Guy Bormans

  118. Guidelines to PET measurements of the target occupancy in the brain for drug development

    Article • European Journal of Pediatrics, August 2016, Springer Science + Business Media

    Adriaan Lammertsma, Guy Bormans

  119. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease

    Article • European Journal of Pediatrics, August 2016, Springer Science + Business Media

    Guy Bormans

  120. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2

    Article • Journal of Nuclear Medicine, July 2016, Society of Nuclear Medicine

    Guy Bormans, Dr Jesus Alcazar

  121. Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: An 18F-FPEB PET Study

    Article • Journal of Nuclear Medicine, June 2016, Society of Nuclear Medicine

    Guy Bormans

  122. Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates

    Article • Journal of Nuclear Medicine, May 2016, Society of Nuclear Medicine

    Guy Bormans, Dr Jesus Alcazar

  123. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

    Article • Frontiers in Pharmacology, March 2016, Frontiers

    Guy Bormans

  124. Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission

    Article • EJNMMI Radiopharmacy and Chemistry, March 2016, Springer Science + Business Media

    Guy Bormans

  125. New Chelators for Low Temperature Al18F-Labeling of Biomolecules

    Article • Bioconjugate Chemistry, February 2016, American Chemical Society (ACS)

    Guy Bormans

  126. Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer18F-FPEB in human brain

    Article • Synapse, February 2016, Wiley

    Guy Bormans

  127. Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807

    Article • Molecular Imaging, January 2016, SAGE Publications

    Guy Bormans, Dr Jesus Alcazar

  128. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide

    Article • Nuclear Medicine and Biology, October 2015, Elsevier

    dr Willy Gsell, Guy Bormans

  129. The effect of anaesthesia on18F-FDG uptake in the rat brain: A fully conscious dynamic study using motion correction

    Article • October 2015, Institute of Electrical & Electronics Engineers (IEEE)

    Guy Bormans

  130. Preclinical Evaluation and Quantification of 18F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5

    Article • Journal of Nuclear Medicine, September 2015, Society of Nuclear Medicine

    Guy Bormans

  131. Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET

    Article • European Journal of Pediatrics, September 2015, Springer Science + Business Media

    Guy Bormans

  132. Retention of [18F]fluoride on reversed phase HPLC columns

    Article • Journal of Pharmaceutical and Biomedical Analysis, July 2015, Elsevier

    Guy Bormans

  133. PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments

    Article • Journal of Nuclear Medicine, June 2015, Society of Nuclear Medicine

    Guy Bormans

  134. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice

    Article • Acta Neuropathologica, April 2015, Springer Science + Business Media

    Guy Bormans

  135. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors

    Article • Neurobiology of Aging, March 2015, Elsevier

    Guy Bormans

  136. Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [18F]MK-9470 PET Study

    Article • Psychotherapy and Psychosomatics, January 2015, Karger Publishers

    Guy Bormans

  137. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice

    Article • Neurobiology of Aging, December 2014, Elsevier

    Guy Bormans, Professor Javier Fernández-Ruiz

  138. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans

    Article • Synapse, September 2014, Wiley

    Guy Bormans

  139. Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A

    Article • Nuclear Medicine and Biology, September 2014, Elsevier

    Guy Bormans

  140. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)

    Article • European Journal of Pediatrics, August 2014, Springer Science + Business Media

    Guy Bormans

  141. PET Radioligands for In Vivo Visualization of Neuroinflammation

    Article • Current Pharmaceutical Design, June 2014, Bentham Science Publishers

    Guy Bormans

  142. Changes in Cerebral CB1Receptor Availability after Acute and Chronic Alcohol Abuse and Monitored Abstinence

    Article • Journal of Neuroscience, February 2014, Society for Neuroscience

    Guy Bormans

  143. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease

    Article • European Neuropsychopharmacology, February 2014, Elsevier

    Guy Bormans

  144. Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)

    Article • Nuclear Medicine and Biology, February 2014, Elsevier

    Guy Bormans

  145. PET imaging shows loss of striatal PDE10A in patients with Huntington disease

    Article • Neurology, January 2014, Wolters Kluwer Health

    Guy Bormans

  146. Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers

    Article • European Journal of Medicinal Chemistry, January 2014, Elsevier

    Guy Bormans

  147. Brain Imaging of Cannabinoid Receptors

    Article • January 2014, Elsevier

    Guy Bormans

  148. 11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists

    Article • Journal of Nuclear Medicine, November 2013, Society of Nuclear Medicine

    Guy Bormans

  149. Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A

    Article • NeuroImage, November 2013, Elsevier

    Guy Bormans

  150. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia

    Article • NeuroImage, October 2013, Elsevier

    marc de hert, Guy Bormans

  151. Lack of endogenous opioid release during sustained visceral pain: A [11C]carfentanil PET study

    Article • Pain, October 2013, Wolters Kluwer Health

    Guy Bormans

  152. Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa

    Article • European Journal of Pediatrics, September 2013, Springer Science + Business Media

    Guy Bormans

  153. In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Guy Bormans

  154. 18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study

    Article • EJNMMI Research, August 2013, Springer Science + Business Media

    Guy Bormans

  155. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis

    Article • Nuclear Medicine and Biology, August 2013, Elsevier

    Guy Bormans

  156. Quantification of 18F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test–Retest Study in Human Brain

    Article • Journal of Nuclear Medicine, July 2013, Society of Nuclear Medicine

    Guy Bormans

  157. Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin αvβ3 expression in vivo

    Article • Nuclear Medicine and Biology, July 2013, Elsevier

    Guy Bormans

  158. Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [18F]FDG and [18F]FECT Functional Mapping of the Mouse Brain

    Article • PLOS One, June 2013, PLOS

    Guy Bormans

  159. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study

    Article • European Journal of Pediatrics, June 2013, Springer Science + Business Media

    Guy Bormans

  160. Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis

    Article • Bioorganic & Medicinal Chemistry Letters, June 2013, Elsevier

    Guy Bormans

  161. Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects

    Article • Molecular Imaging and Biology, March 2013, Springer Science + Business Media

    Guy Bormans

  162. Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type‐1 receptors

    Article • Journal of Labelled Compounds and Radiopharmaceuticals, March 2013, Wiley

    Guy Bormans

  163. Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human

    Article • NeuroImage, March 2013, Elsevier

    Guy Bormans

  164. New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation

    Article • ACS Chemical Neuroscience, February 2013, American Chemical Society (ACS)

    Guy Bormans

  165. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy

    Article • The Journal of Headache and Pain, February 2013, Springer Science + Business Media

    Guy Bormans

  166. 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity

    Article • Journal of Nuclear Medicine, January 2013, Society of Nuclear Medicine

    Guy Bormans

  167. Preclinical evaluation of carbon-11 and fluorine-18 sulfonamide derivatives for in vivo radiolabeling of erythrocytes

    Article • EJNMMI Research, January 2013, Springer Science + Business Media

    Guy Bormans

  168. Synthesis and biological evaluation of [11C]SB366791: A new PET-radioligand for in vivo imaging of the TRPV1 receptor

    Article • Nuclear Medicine and Biology, January 2013, Elsevier

    Guy Bormans

  169. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging

    Article • European Journal of Pediatrics, November 2012, Springer Science + Business Media

    Guy Bormans

  170. Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET

    Article • Nuclear Medicine and Biology, November 2012, Elsevier

    Guy Bormans

  171. Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging

    Article • Journal of Medicinal Chemistry, October 2012, American Chemical Society (ACS)

    Guy Bormans, Dr Jesus Alcazar

  172. Optimized In Vivo Detection of Dopamine Release Using 18F-Fallypride PET

    Article • Journal of Nuclear Medicine, August 2012, Society of Nuclear Medicine

    Guy Bormans

  173. Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model

    Article • European Journal of Pediatrics, August 2012, Springer Science + Business Media

    Guy Bormans

  174. Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?

    Article • International Journal of Radiation Oncology*Biology*Physics, August 2012, Elsevier

    Guy Bormans

  175. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

    Article • Clinical Pharmacology & Therapeutics, June 2012, Wiley

    Guy Bormans

  176. Preclinical evaluation and quantification of [18F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain

    Article • European Journal of Pediatrics, June 2012, Springer Science + Business Media

    Guy Bormans

  177. Noninvasive Molecular Imaging of Neuroinflammation

    Article • Journal of Cerebral Blood Flow & Metabolism, May 2012, SAGE Publications

    Guy Bormans

  178. Recent Advances in Positron Emission Tomography (PET) Radiotracers for Imaging Phosphodiesterases

    Article • Current Topics in Medicinal Chemistry, May 2012, Bentham Science Publishers

    Guy Bormans, Dr Jesus Alcazar

  179. Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy

    Article • Investigational New Drugs, December 2011, Springer Science + Business Media

    Guy Bormans

  180. Measuring extrastriatal dopamine release during a reward learning task

    Article • Human Brain Mapping, November 2011, Wiley

    Guy Bormans